Stay updated on Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial page.

Latest updates to the Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial page
- CheckyesterdayNo Change Detected
- Check8 days agoChange DetectedThe NIH website transition banner about updated terminology and related FAQs is no longer displayed.SummaryDifference1%

- Check15 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0; the page still displays a 403 Forbidden error.SummaryDifference0.2%

- Check22 days agoChange DetectedA banner announces an NIH-wide transition from using “Artificial Intelligence” to “Super Intelligence” and links to updates and FAQs.SummaryDifference1%

- Check28 days agoChange DetectedThe ClinicalTrials.gov footer revision changed from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check35 days agoChange DetectedThe site footer revision identifier changed from v3.7.0 to v3.7.1. The study page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check56 days agoChange DetectedThe page now displays a 403 Forbidden state with a minimal header and Home button, and a large portion of the previous study-content sections has been removed, resulting in an error-page display rather than the full study details.SummaryDifference19%

Stay in the know with updates to Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab & Enobosarm in AR+ Metastatic TNBC Clinical Trial page.